Apeloa Pharmaceutical Subsidiary Gains Approval for Fuzereisai Active Ingredient Application

Stock News08-05

Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., has received the "Chemical Bulk Drug Listing Application Approval Notice" for the active pharmaceutical ingredient (API) Fuzereisai from the National Medical Products Administration.

This API is indicated for the treatment of adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). The approval highlights the company's comprehensive competitiveness in CDMO business aspects, including research and development, production, and system assurance. It is expected to positively impact the company's future operations, ensure a stable supply of Fuzereisai API, and assist partners in advancing product development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment